Cholangitis is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cholangitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cholangitis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Cholangitis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cholangitis overview

Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts. Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice (yellowing of the skin and eyes); fever and chills; nausea, vomiting, and loss of appetite; dark urine and pale stools; and generalized weakness or fatigue.

For a complete picture of PTSR and LoA scores for drugs in Cholangitis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.